{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:33:53Z","timestamp":1791293633770,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:00:00Z","timestamp":1370563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T00:00:00Z","timestamp":1370563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nri3463","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T09:31:28Z","timestamp":1370597488000},"page":"535-542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end"],"prefix":"10.1038","volume":"13","author":[{"given":"Markus H.","family":"Heim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,7]]},"reference":[{"key":"BFnri3463_CR1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558\u2013567 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"BFnri3463_CR2","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1128\/JVI.75.15.7059-7066.2001","volume":"75","author":"CB Bigger","year":"2001","unstructured":"Bigger, C. B., Brasky, K. M. & Lanford, R. E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75, 7059\u20137066 (2001).","journal-title":"J. Virol."},{"key":"BFnri3463_CR3","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1073\/pnas.202608299","volume":"99","author":"R Thimme","year":"2002","unstructured":"Thimme, R. et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA 99, 15661\u201315668 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3463_CR4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2012.05.044","volume":"143","author":"MT Dill","year":"2012","unstructured":"Dill, M. T. et al. Interferon-\u03b3-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 143, 777\u2013786.e1\u20136 (2012).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer, G. M. & Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 345, 41\u201352 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3463_CR6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359\u2013362 (1989).","journal-title":"Science"},{"key":"BFnri3463_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","volume":"5","author":"D Moradpour","year":"2007","unstructured":"Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nature Rev. Microbiol. 5, 453\u2013463 (2007).","journal-title":"Nature Rev. Microbiol."},{"key":"BFnri3463_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-\u03b1 therapy. Science 282, 103\u2013107 (1998).","journal-title":"Science"},{"key":"BFnri3463_CR9","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","volume":"108","author":"MH Powdrill","year":"2011","unstructured":"Powdrill, M. H. et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl Acad. Sci. USA 108, 20509\u201320513 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3463_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-59745-394-3_4","volume":"510","author":"C Kuiken","year":"2009","unstructured":"Kuiken, C. & Simmonds, P. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510, 33\u201353 (2009).","journal-title":"Methods Mol. Biol."},{"key":"BFnri3463_CR11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle, J. H. et al. Treatment of chronic non-A,non-B hepatitis with recombinant human \u03b1-interferon. A preliminary report. New Engl. J. Med. 315, 1575\u20131578 (1986).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.10.005","volume":"58","author":"MH Heim","year":"2013","unstructured":"Heim, M. H. Innate immunity and HCV. J. Hepatol. 58, 564\u2013574 (2013).","journal-title":"J. Hepatol."},{"key":"BFnri3463_CR13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M. P. et al. Peginterferon-\u03b12b plus ribavirin compared with interferon-\u03b12b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958\u2013965 (2001).","journal-title":"Lancet"},{"key":"BFnri3463_CR14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon-\u03b12a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR15","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/MCB.00224-09","volume":"29","author":"M Sarasin-Filipowicz","year":"2009","unstructured":"Sarasin-Filipowicz, M. et al. \u03b1-interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43. Mol. Cell. Biol. 29, 4841\u20134851 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"BFnri3463_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"BFnri3463_CR17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy. Nature Genet. 41, 1100\u20131104 (2009).","journal-title":"Nature Genet."},{"key":"BFnri3463_CR18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nature Genet. 41, 1105\u20131109 (2009).","journal-title":"Nature Genet."},{"key":"BFnri3463_CR19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338\u20131345, 1345.e1\u20137 (2010).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature Genet. 45, 164\u2013171 (2013).","journal-title":"Nature Genet."},{"key":"BFnri3463_CR21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"BFnri3463_CR22","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.R700004200","volume":"282","author":"S Pestka","year":"2007","unstructured":"Pestka, S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047\u201320051 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnri3463_CR23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr.","year":"1994","unstructured":"Darnell, J. E. Jr., Kerr, I. M. & Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415\u20131421 (1994).","journal-title":"Science"},{"key":"BFnri3463_CR24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","volume":"25","author":"AH van Boxel-Dezaire","year":"2006","unstructured":"van Boxel-Dezaire, A. H., Rani, M. R. & Stark, G. R. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361\u2013372 (2006).","journal-title":"Immunity"},{"key":"BFnri3463_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","volume":"25","author":"DB Stetson","year":"2006","unstructured":"Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity 25, 373\u2013381 (2006).","journal-title":"Immunity"},{"key":"BFnri3463_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2008","unstructured":"Sadler, A. J. & Williams, B. R. Interferon-inducible antiviral effectors. Nature Rev. Immunol. 8, 559\u2013568 (2008).","journal-title":"Nature Rev. Immunol."},{"key":"BFnri3463_CR27","doi-asserted-by":"crossref","first-page":"34064","DOI":"10.1074\/jbc.M605771200","volume":"281","author":"F Terenzi","year":"2006","unstructured":"Terenzi, F., Hui, D. J., Merrick, W. C. & Sen, G. C. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J. Biol. Chem. 281, 34064\u201334071 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFnri3463_CR28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"BFnri3463_CR29","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/hep.25908","volume":"56","author":"P Metz","year":"2012","unstructured":"Metz, P. et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56, 2082\u20132093 (2012).","journal-title":"Hepatology"},{"key":"BFnri3463_CR30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep.26066","volume":"57","author":"C Wilkins","year":"2013","unstructured":"Wilkins, C. et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57, 461\u2013469 (2013).","journal-title":"Hepatology"},{"key":"BFnri3463_CR31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature10921","volume":"484","author":"AR Everitt","year":"2012","unstructured":"Everitt, A. R. et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484, 519\u2013523 (2012).","journal-title":"Nature"},{"key":"BFnri3463_CR32","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105, 7034\u20137039 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3463_CR33","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20021522","volume":"197","author":"M Dalod","year":"2003","unstructured":"Dalod, M. et al. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon-\u03b1\/\u03b2. J. Exp. Med. 197, 885\u2013898 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnri3463_CR34","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","volume":"169","author":"KB Nguyen","year":"2002","unstructured":"Nguyen, K. B. et al. Coordinated and distinct roles for IFN-\u03b1\u03b2, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279\u20134287 (2002).","journal-title":"J. Immunol."},{"key":"BFnri3463_CR35","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.4049\/jimmunol.165.7.3571","volume":"165","author":"CK Lee","year":"2000","unstructured":"Lee, C. K. et al. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165, 3571\u20133577 (2000).","journal-title":"J. Immunol."},{"key":"BFnri3463_CR36","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.4049\/jimmunol.176.6.3315","volume":"176","author":"C Havenar-Daughton","year":"2006","unstructured":"Havenar-Daughton, C., Kolumam, G. A. & Murali-Krishna, K. Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176, 3315\u20133319 (2006).","journal-title":"J. Immunol."},{"key":"BFnri3463_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. & Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202, 637\u2013650 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnri3463_CR38","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.176.8.4525","volume":"176","author":"P Aichele","year":"2006","unstructured":"Aichele, P. et al. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176, 4525\u20134529 (2006).","journal-title":"J. Immunol."},{"key":"BFnri3463_CR39","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1084\/jem.20030239","volume":"197","author":"NH Shoukry","year":"2003","unstructured":"Shoukry, N. H. et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197, 1645\u20131655 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnri3463_CR40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","volume":"302","author":"A Grakoui","year":"2003","unstructured":"Grakoui, A. et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659\u2013662 (2003).","journal-title":"Science"},{"key":"BFnri3463_CR41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/gast.2002.36045","volume":"123","author":"SM Kamal","year":"2002","unstructured":"Kamal, S. M., Fehr, J., Roesler, B., Peters, T. & Rasenack, J. W. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123, 1070\u20131083 (2002).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(00)70217-4","volume":"118","author":"ME Cramp","year":"2000","unstructured":"Cramp, M. E. et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118, 346\u2013355 (2000).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/jhep.2002.35344","volume":"36","author":"E Barnes","year":"2002","unstructured":"Barnes, E. et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36, 743\u2013754 (2002).","journal-title":"Hepatology"},{"key":"BFnri3463_CR44","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1086\/513278","volume":"195","author":"JH Aberle","year":"2007","unstructured":"Aberle, J. H. et al. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon\/ribavirin therapy correlate with faster, but not sustained, viral clearance. J. Infect. Dis. 195, 1315\u20131319 (2007).","journal-title":"J. Infect. Dis."},{"key":"BFnri3463_CR45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2007.06.059","volume":"133","author":"M Pilli","year":"2007","unstructured":"Pilli, M. et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133, 1132\u20131143 (2007).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/287411a0","volume":"287","author":"DV Goeddel","year":"1980","unstructured":"Goeddel, D. V. et al. Human leukocyte interferon produced by E. coli is biologically active. Nature 287, 411\u2013416 (1980).","journal-title":"Nature"},{"key":"BFnri3463_CR47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/284316a0","volume":"284","author":"S Nagata","year":"1980","unstructured":"Nagata, S. et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284, 316\u2013320 (1980).","journal-title":"Nature"},{"key":"BFnri3463_CR48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(80)90885-5","volume":"1","author":"W Weimar","year":"1980","unstructured":"Weimar, W. et al. Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet 1, 336\u2013338 (1980).","journal-title":"Lancet"},{"key":"BFnri3463_CR49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/143.6.772","volume":"143","author":"GH Scullard","year":"1981","unstructured":"Scullard, G. H. et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J. Infect. Dis. 143, 772\u2013783 (1981).","journal-title":"J. Infect. Dis."},{"key":"BFnri3463_CR50","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis, G. L. et al. Treatment of chronic hepatitis C with recombinant interferon-\u03b1. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New Engl. J. Med. 321, 1501\u20131506 (1989).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR51","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","volume":"321","author":"AM Di Bisceglie","year":"1989","unstructured":"Di Bisceglie, A. M. et al. Recombinant interferon-\u03b1 therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New Engl. J. Med. 321, 1506\u20131510 (1989).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin, P. et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-\u03b1 therapy. Ann. Internal Med. 127, 875\u2013881 (1997).","journal-title":"Ann. Internal Med."},{"key":"BFnri3463_CR53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289\u2013293 (1996).","journal-title":"Hepatology"},{"key":"BFnri3463_CR54","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","volume":"56","author":"R D'Ambrosio","year":"2012","unstructured":"D'Ambrosio, R. et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56, 532\u2013543 (2012).","journal-title":"Hepatology"},{"key":"BFnri3463_CR55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0168-8278(95)80052-2","volume":"23","author":"R Lin","year":"1995","unstructured":"Lin, R., Roach, E., Zimmerman, M., Strasser, S. & Farrell, G. C. Interferon-\u03b12b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J. Hepatol 23, 487\u2013496 (1995).","journal-title":"J. Hepatol"},{"key":"BFnri3463_CR56","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","volume":"332","author":"T Poynard","year":"1995","unstructured":"Poynard, T. et al. A comparison of three interferon-\u03b12b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N. Engl. J. Med. 332, 1457\u20131462 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3463_CR57","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","volume":"337","author":"O Reichard","year":"1991","unstructured":"Reichard, O., Andersson, J., Schvarcz, R. & Weiland, O. Ribavirin treatment for chronic hepatitis C. Lancet 337, 1058\u20131061 (1991).","journal-title":"Lancet"},{"key":"BFnri3463_CR58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","volume":"16","author":"AM Di Bisceglie","year":"1992","unstructured":"Di Bisceglie, A. M. et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16, 649\u2013654 (1992).","journal-title":"Hepatology"},{"key":"BFnri3463_CR59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0168-8278(97)80103-1","volume":"26","author":"SW Schalm","year":"1997","unstructured":"Schalm, S. W. et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26, 961\u2013966 (1997).","journal-title":"J. Hepatol."},{"key":"BFnri3463_CR60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jmv.1890460110","volume":"46","author":"R Schvarcz","year":"1995","unstructured":"Schvarcz, R., Yun, Z. B., Sonnerborg, A. & Weiland, O. Combined treatment with interferon-\u03b12b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43\u201347 (1995).","journal-title":"J. Med. Virol."},{"key":"BFnri3463_CR61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","volume":"351","author":"O Reichard","year":"1998","unstructured":"Reichard, O. et al. Randomised, double-blind, placebo-controlled trial of interferon-\u03b12b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351, 83\u201387 (1998).","journal-title":"Lancet"},{"key":"BFnri3463_CR62","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison, J. G. et al. Interferon-\u03b12b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New Engl. J. Med. 339, 1485\u20131492 (1998).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld, J. J. & Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967\u2013972 (2005).","journal-title":"Nature"},{"key":"BFnri3463_CR64","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.coviro.2011.10.030","volume":"1","author":"J Paeshuyse","year":"2011","unstructured":"Paeshuyse, J., Dallmeier, K. & Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr. Opin. Virol. 1, 590\u2013598 (2011).","journal-title":"Curr. Opin. Virol."},{"key":"BFnri3463_CR65","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem, S. et al. Peginterferon-\u03b12a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666\u20131672 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3463_CR66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"KL Lindsay","year":"2001","unstructured":"Lindsay, K. L. et al. A randomized, double-blind trial comparing pegylated interferon-\u03b12b to interferon-\u03b12b as initial treatment for chronic hepatitis C. Hepatology 34, 395\u2013403 (2001).","journal-title":"Hepatology"},{"key":"BFnri3463_CR67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0021-9258(17)42492-6","volume":"261","author":"AC Larner","year":"1986","unstructured":"Larner, A. C., Chaudhuri, A. & Darnell, J. E. Jr. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J. Biol. Chem. 261, 453\u2013459 (1986).","journal-title":"J. Biol. Chem."},{"key":"BFnri3463_CR68","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.24189","volume":"53","author":"Z Makowska","year":"2011","unstructured":"Makowska, Z., Duong, F. H., Trincucci, G., Tough, D. F. & Heim, M. H. Interferon-\u03b2 and interferon-\u03bb signaling is not affected by interferon-induced refractoriness to interferon-\u03b1 in vivo. Hepatology 53, 1154\u20131163 (2011).","journal-title":"Hepatology"},{"key":"BFnri3463_CR69","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. New Engl. J. Med. 364, 1195\u20131206 (2011).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR70","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl. J. Med. 364, 2405\u20132416 (2011).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR71","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","volume":"19","author":"F Poordad","year":"2012","unstructured":"Poordad, F. & Dieterich, D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J. Viral Hepat. 19, 449\u2013464 (2012).","journal-title":"J. Viral Hepat."},{"key":"BFnri3463_CR72","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","volume":"56","author":"C Sarrazin","year":"2012","unstructured":"Sarrazin, C., Hezode, C., Zeuzem, S. & Pawlotsky, J. M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56, S88\u2013S100 (2012).","journal-title":"J. Hepatol."},{"key":"BFnri3463_CR73","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. New Engl. J. Med. 366, 216\u2013224 (2012).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR74","doi-asserted-by":"crossref","first-page":"15669","DOI":"10.1073\/pnas.202608199","volume":"99","author":"AI Su","year":"2002","unstructured":"Su, A. I. et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad. Sci. USA 99, 15669\u201315674 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3463_CR75","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.20239","volume":"39","author":"ME Major","year":"2004","unstructured":"Major, M. E. et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39, 1709\u20131720 (2004).","journal-title":"Hepatology"},{"key":"BFnri3463_CR76","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nature04193","volume":"437","author":"E Meylan","year":"2005","unstructured":"Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167\u20131172 (2005).","journal-title":"Nature"},{"key":"BFnri3463_CR77","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1128\/JVI.73.10.8469-8475.1999","volume":"73","author":"MH Heim","year":"1999","unstructured":"Heim, M. H., Moradpour, D. & Blum, H. E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J. Virol. 73, 8469\u20138475 (1999).","journal-title":"J. Virol."},{"key":"BFnri3463_CR78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.chom.2009.11.004","volume":"6","author":"U Garaigorta","year":"2009","unstructured":"Garaigorta, U. & Chisari, F. V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6, 513\u2013522 (2009).","journal-title":"Cell Host Microbe"},{"key":"BFnri3463_CR79","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20050121","volume":"201","author":"AL Cox","year":"2005","unstructured":"Cox, A. L. et al. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201, 1741\u20131752 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnri3463_CR80","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1074-7613(01)00245-X","volume":"15","author":"AL Erickson","year":"2001","unstructured":"Erickson, A. L. et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883\u2013895 (2001).","journal-title":"Immunity"},{"key":"BFnri3463_CR81","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1084\/jem.20042284","volume":"201","author":"I Tester","year":"2005","unstructured":"Tester, I. et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 201, 1725\u20131731 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnri3463_CR82","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.01177-06","volume":"80","author":"S Urbani","year":"2006","unstructured":"Urbani, S. et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80, 11398\u201311403 (2006).","journal-title":"J. Virol."},{"key":"BFnri3463_CR83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000329807","volume":"29","author":"C Neumann-Haefelin","year":"2011","unstructured":"Neumann-Haefelin, C. & Thimme, R. Success and failure of virus-specific T cell responses in hepatitis C virus infection. Dig. Dis. 29, 416\u2013422 (2011).","journal-title":"Dig. Dis."},{"key":"BFnri3463_CR84","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","volume":"128","author":"L Chen","year":"2005","unstructured":"Chen, L. et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128, 1437\u20131444 (2005).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR85","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/gut.2007.128611","volume":"57","author":"T Asselah","year":"2008","unstructured":"Asselah, T. et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57, 516\u2013524 (2008).","journal-title":"Gut"},{"key":"BFnri3463_CR86","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","volume":"46","author":"JJ Feld","year":"2007","unstructured":"Feld, J. J. et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46, 1548\u20131563 (2007).","journal-title":"Hepatology"},{"key":"BFnri3463_CR87","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","volume":"140","author":"MT Dill","year":"2011","unstructured":"Dill, M. T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021\u20131031 (2011).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR88","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","volume":"139","author":"M Honda","year":"2010","unstructured":"Honda, M. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499\u2013509 (2010).","journal-title":"Gastroenterology"},{"key":"BFnri3463_CR89","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","volume":"52","author":"TJ Urban","year":"2010","unstructured":"Urban, T. J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888\u20131896 (2010).","journal-title":"Hepatology"},{"key":"BFnri3463_CR90","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.23426","volume":"51","author":"P Bellecave","year":"2010","unstructured":"Bellecave, P. et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 51, 1127\u20131136 (2010).","journal-title":"Hepatology"},{"key":"BFnri3463_CR91","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","volume":"52","author":"AJ Muir","year":"2010","unstructured":"Muir, A. J. et al. Phase 1b study of pegylated interferon-\u03bb1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822\u2013832 (2010).","journal-title":"Hepatology"},{"key":"BFnri3463_CR92","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198\u2013201 (2010).","journal-title":"Science"},{"key":"BFnri3463_CR93","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","volume":"52","author":"N Akuta","year":"2010","unstructured":"Akuta, N. et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin-28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52, 421\u2013429 (2010).","journal-title":"Hepatology"},{"key":"BFnri3463_CR94","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. New Engl. J. Med. 364, 2417\u20132428 (2011).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR95","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New Engl. J. Med. 364, 1207\u20131217 (2011).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR96","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nature04078","volume":"436","author":"M Gale Jr","year":"2005","unstructured":"Gale, M. Jr & Foy, E. M. Evasion of intracellular host defence by hepatitis C virus. Nature 436, 939\u2013945 (2005).","journal-title":"Nature"},{"key":"BFnri3463_CR97","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1574-6976.2011.00319.x","volume":"36","author":"R Thimme","year":"2012","unstructured":"Thimme, R., Binder, M. & Bartenschlager, R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol. Rev. 36, 663\u2013683 (2012).","journal-title":"FEMS Microbiol. Rev."},{"key":"BFnri3463_CR98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko, S. V. et al. IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4, 69\u201377 (2003).","journal-title":"Nature Immunol."},{"key":"BFnri3463_CR99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunol. 4, 63\u201368 (2003).","journal-title":"Nature Immunol."},{"key":"BFnri3463_CR100","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","volume":"22","author":"JW Yu","year":"2007","unstructured":"Yu, J. W., Wang, G. Q., Sun, L. J., Li, X. G. & Li, S. C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon-\u03b12a and ribavirin. J. Gastroenterol. Hepatol. 22, 832\u2013836 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnri3463_CR101","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"D Lamarre","year":"2003","unstructured":"Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186\u2013189 (2003).","journal-title":"Nature"},{"key":"BFnri3463_CR102","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(75)90234-2","volume":"2","author":"HJ Alter","year":"1975","unstructured":"Alter, H. J. et al. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 2, 838\u2013841 (1975).","journal-title":"Lancet"},{"key":"BFnri3463_CR103","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM197504102921502","volume":"292","author":"SM Feinstone","year":"1975","unstructured":"Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J. & Holland, P. V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. New Engl. J. Med. 292, 767\u2013770 (1975).","journal-title":"New Engl. J. Med."},{"key":"BFnri3463_CR104","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","volume":"87","author":"JL Kim","year":"1996","unstructured":"Kim, J. L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343\u2013355 (1996).","journal-title":"Cell"},{"key":"BFnri3463_CR105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","volume":"7","author":"H Ago","year":"1999","unstructured":"Ago, H. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7, 1417\u20131426 (1999).","journal-title":"Structure"},{"key":"BFnri3463_CR106","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","volume":"6","author":"CA Lesburg","year":"1999","unstructured":"Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6, 937\u2013943 (1999).","journal-title":"Nature Struct. Biol."},{"key":"BFnri3463_CR107","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature03580","volume":"435","author":"TL Tellinghuisen","year":"2005","unstructured":"Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374\u2013379 (2005).","journal-title":"Nature"},{"key":"BFnri3463_CR108","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791\u2013796 (2005).","journal-title":"Nature Med."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nri3463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nri3463","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nri3463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T10:30:15Z","timestamp":1659177015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nri3463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,7]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnri3463"],"URL":"https:\/\/doi.org\/10.1038\/nri3463","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,7]]},"assertion":[{"value":"7 June 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}